Novavax, Inc. NVAX shares are buying and selling increased by 2.80% to $41.47, although off the session excessive of $43.06 after the corporate introduced its Novaxovid COVID-19 vaccine has been authorised in South Korea to be used in adolescents aged 12 by way of 17.
Novavax says the approval was based mostly on knowledge from the continuing pediatric growth of the Part 3 PREVENT-19 trial of two,247 adolescents aged 12 by way of 17 years throughout 73 websites within the U.S., to guage the security, effectiveness (immunogenicity), and efficacy of Nuvaxovid.
Within the trial, Novavax says Nuvaxovid achieved its major effectiveness endpoint and demonstrated 80% medical efficacy general at a time when the Delta variant was the predominant circulating SARS-CoV-2 pressure within the U.S.
“Right this moment’s approval in South Korea is a vital step in guaranteeing broad international entry to a protein-based vaccine possibility,” stated Stanley C. Erck, President and Chief Govt Officer, Novavax.
“We’re happy to collaborate with SK bioscience to supply our vaccine to adolescents aged 12 by way of 17 in South Korea.”
In keeping with knowledge from Benzinga Professional, Novavax has a 52-week excessive of $277.80 and a 52-week low of $34.88.